TMEM106B
<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">TMEM106B</th>
</tr>
<tr>
<td class="label">Gene</td>
<td>[TMEM106B](/genes/tmem106b)</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/Q9NUM4" target="_blank">Q9NUM4</a></td>
</tr>
<tr>
<td class="label">PDB</td>
<td>N/A</td>
</tr>
<tr>
<td class="label">Mol. Weight</td>
<td>31 kDa</td>
</tr>
<tr>
<td class="label">Localization</td>
<td>Late endosomes and lysosomes</td>
</tr>
<tr>
<td class="label">Family</td>
<td>Type II lysosomal transmembrane protein family</td>
</tr>
<tr>
<td class="label">Diseases</td>
<td>[Frontotemporal Dementia](/diseases/ftd), [ALS](/diseases/als), [LATE](/diseases/late-encephalopathy)</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a>, <a href="/wiki/amyotrophic-lateral-sclerosis" style="color:#ef9a9a">Amyotrophic Lateral Sclerosis</a>, <a href="/wiki/dementia" style="color:#ef9a9a">Dementia</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">164 edges</a></td>
</tr>
</table>
TMEM106B
TMEM106B (Transmembrane Protein 106B) is a 323-amino acid type II lysosomal transmembrane protein encoded by the [TMEM106B](/genes/tmem106b) gene on chromosome 7p21.1. Originally identified as a genetic risk factor for [frontotemporal lobar degeneration](/diseases/frontotemporal-dementia) (FTLD) through genome-wide association studies, TMEM106B has emerged as a critical regulator of lysosomal function with implications for multiple neurodegenerative diseases including [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), and [amyotrophic lateral sclerosis](/diseases/als) [@common2010].
Gene and Protein Structure
The TMEM106B gene spans approximately 17 kb and consists of 9 exons. The protein localizes primarily to the membrane of late endosomes and lysosomes, where it exists as a homodimer. Structural studies indicate that TMEM106B contains a short N-terminal cytoplasmic domain (approximately 10 amino acids), a single transmembrane helix, and a large C-terminal luminal domain that faces the interior of lysosomes [@uniprot].
The TMEM106B protein exhibits several distinctive features:
- Molecular weight: Approximately 31 kDa
- Topology: Type II transmembrane protein (N-out, C-in)
- Oligomerization: Forms homodimers and higher-order oligomers
- Post-translational modifications: N-glycosylation in the luminal domain
- Tissue distribution: Highest expression in brain, particularly in neurons and microglia
Lysosomal Biology
TMEM106B functions as a master regulator of lysosomal function, affecting multiple aspects of lysosomal biology that are critical for neuronal health [@vanmechelen2019]:
Lysosomal Acidification and Hydrolase Activity
Proper lysosomal function requires an acidic interior (pH 4.5-5.0) maintained by v-type ATPases. TMEM106B contributes to:
- Ion homeostasis: Regulation of proton pump assembly
- Hydrolase activation: Optimal pH for cathepsin proteases
- Cargo degradation: Efficient breakdown of proteins, lipids, and nucleic acids
Membrane Trafficking
TMEM106B influences endosomal-lysosomal trafficking through:
- Late endosome maturation: Coordination of cargo sorting
- Lysosomal movement: Regulation of motor protein interactions
- Membrane fusion: ESCRT-dependent and independent pathways
Autophagy Regulation
A critical function of TMEM106B is its role in autophagy, the cellular recycling system that degrades damaged organelles and protein aggregates:
Autophagosome formation: TMEM106B affects upstream initiation steps
Autophagosome-lysosome fusion: Direct interaction with SNARE proteins
Lysosomal degradation: Optimal function of the autolysosomal compartment
Aggregate clearance: Particularly important for neurons handling TDP-43 and [alpha-synuclein](/proteins/alpha-synuclein) aggregatesGenetic Variants and Disease Risk
GWAS Discovery and Replication
The TMEM106B locus was first identified as a major risk factor for FTLD in a landmark genome-wide association study that identified the single nucleotide polymorphism (SNP) rs1990620 on chromosome 7p21 [@common2010]. This finding has been replicated in multiple independent cohorts and expanded to include:
- rs3173615 (T185S): The key amino acid change distinguishing risk alleles
- Haplotypic structure: Multiple independent signals at the locus
- Ancestral effects: Population-specific allele frequencies
The T185S Functional Polymorphism
The amino acid substitution threonine to serine at position 185 (T185S) represents the most functionally significant TMEM106B variant:
| Allele | Effect | Frequency (European) | Disease Association |
|--------|--------|---------------------|-------------------|
| T185 (protective) | Higher TMEM106B expression | ~40% | Reduced FTLD risk |
| S185 (risk) | Lower TMEM106B expression | ~60% | Increased FTLD risk, especially with GRN mutations |
Gene-Disease Interactions
TMEM106B acts as a powerful modifier of several monogenic neurodegenerative conditions:
Progranulin (GRN) Mutations
TMEM106B strongly modifies disease onset and phenotype in individuals with [GRN](/genes/grn) mutations:
- Age of onset: Risk alleles accelerate onset by 5-10 years
- Clinical phenotype: Influences presentation (behavioral vs. language variant)
- TDP-43 pathology: Modifies burden and distribution of TDP-43 inclusions [@schwenk2014]
C9orf72 Expansions
The hexanucleotide repeat expansion in [C9orf72](/genes/c9orf72) represents the most common genetic cause of FTLD/ALS. TMEM106B risk variants:
- Modify disease penetrance: Earlier onset in carriers of both risk factors
- Affect lysosomal function: Synergistic effects on endolysosomal pathways [@cm2024]
- Influence clinical phenotype: Bias toward ALS phenotype with risk alleles
TMEM106B and TDP-43 Pathology
A central finding in TMEM106B biology is its relationship with TDP-43 proteinopathy, the characteristic pathological hallmark of most FTLD subtypes and ALS [@finch2011]:
TDP-43 Biology
TAR DNA-binding protein 43 (TDP-43) is a nuclear RNA-binding protein that:
- Regulates RNA splicing, transport, and translation
- Forms stress granules under cellular stress
- Aggregates in pathological inclusions in FTLD and ALS
TMEM106B-TDP-43 Interactions
Genetic interaction: TMEM106B risk variants associate with increased TDP-43 pathology
Regional specificity: Effects most pronounced in the dentate gyrus and frontal cortex
Burden correlation: Higher TDP-43 burden correlates with TMEM106B risk alleles
Core deposition: TMEM106B itself can form pathological cores that colocalize with TDP-43 [@cm2024]Therapeutic Implications
Understanding the TMEM106B-TDP-43 relationship has opened several therapeutic avenues:
- Gene therapy: Increase TMEM106B expression to enhance lysosomal function
- Small molecules: Enhance lysosomal acidification and function
- TDP-43 targeting: Indirect effects through improved cellular clearance
Interaction with Other Neurodegeneration Proteins
Progranulin (PGRN)
TMEM106B and progranulin have a complex genetic and functional relationship [@brett2022]:
- Genetic: TMEM106B modifies PGRN-FTD phenotype
- Protein-protein interaction: Direct physical binding
- Lysosomal colocalization: Both proteins traffic through endolysosomal system
- Functional compensation: TMEM106B may partially compensate for reduced PGRN
CHMP2B
Mutations in CHMP2B cause a rare form of FTLD (FTD-3). TMEM106B associates with CHMP2B as part of the ESCRT-III complex involved in membrane remodeling [@cm2015].
Beta-amyloid and Tau
Emerging evidence links TMEM106B to [Alzheimer's disease](/diseases/alzheimers-disease) pathology:
- Amyloid interaction: TMEM106B expression affected by [amyloid-beta](/proteins/amyloid-beta) accumulation
- Tau pathology: TMEM106B variants influence tau burden in AD brain
- Microglial modulation: Effects on microglial lysosomal function
Cell-Type Specific Effects
Neurons
TMEM106B is highly expressed in neurons where it:
- Maintains neuronal lysosomal function
- Protects against proteotoxic stress
- Supports dendritic and axonal health
- Regulates synaptic vesicle trafficking
Microglia
Microglial TMEM106B affects:
- Inflammatory responses: Lysosomal function in immune activation
- Phagocytosis: Clearance of debris and protein aggregates
- Aging effects: Age-related changes in microglial lysosomes
Oligodendrocytes
Myelinating oligodendrocytes require TMEM106B for:
- Myelin maintenance: Lysosomal function in myelin turnover
- Energy metabolism: Support for highly metabolic cells
Biomarker Potential
TMEM106B has significant potential as a biomarker for neurodegenerative disease:
Genetic Biomarkers
- Risk stratification: TMEM106B genotyping for family risk assessment
- Predictive testing: Age of onset prediction in GRN mutation carriers
- Patient selection: Enrichment for clinical trials
Fluid Biomarkers
- Blood TMEM106B: Correlates with disease status and progression
- CSF TMEM106B: Emerging as a potential diagnostic marker
- Combination panels: TMEM106B with other lysosomal proteins
Imaging Biomarkers
- PET ligands: Development of TMEM106B-specific imaging agents
- MRI correlations: TMEM106B risk variants associate with cortical atrophy patterns [@nichols2015]
Therapeutic Strategies
Gene Therapy Approaches
- Viral vectors: AAV-mediated TMEM106B overexpression
- Conditional expression: Cell-type specific delivery
- Allele-specific: Targeting protective alleles
Small Molecule Modulators
- Lysosomal function enhancers: Improve acidification and hydrolase activity
- TFEB agonists: Activate lysosomal biogenesis via mTOR inhibition
- Autophagy inducers: Enhance cellular clearance pathways
Combination Approaches
- Dual targeting: TMEM106B + progranulin modulation
- Multimodal therapy: Gene therapy + small molecules
- Disease-modifying combinations: Address multiple pathways
TMEM106B in Other Neurological Conditions
Parkinson's Disease
Emerging evidence links TMEM106B to [Parkinson's disease](/diseases/parkinsons-disease):
- Genetic association: PD risk variants near TMEM106B locus
- Lysosomal dysfunction: Central to PD pathogenesis
- Alpha-synuclein interaction: Effects on [alpha-synuclein](/proteins/alpha-synuclein) clearance [@lynch2019]
Normal Aging
TMEM106B expression changes with age:
- Age-related decline: Reduced expression in aged brain
- Cognitive effects: TMEM106B variants affect cognitive trajectories
- Vulnerability: Age-related changes unmask disease effects
Animal Models and Experimental Systems
Mouse Models
- Tmem106b knockout: Lethal prenatally, highlighting essential function
- Transgenic overexpression: Rescue of lysosomal phenotypes
- Humanized mice: Expressing human TMEM106B variants
Cell Culture Models
- iPSC-derived neurons: Patient-specific TMEM106B variants
- Microglia: Role in neuroinflammation
- Organoids: Brain organoid models of TMEM106B dysfunction
Research Challenges and Future Directions
Structural biology: Complete high-resolution structure of TMEM106B
Mechanistic studies: Elucidate exact molecular functions
Therapeutic development: Progress from basic biology to clinical applications
Biomarker validation: Establish clinical utility of TMEM106B markers
Personalized medicine: Stratify patients based on TMEM106B genotypeSee Also
- [Genes Index](/genes)
- [Frontotemporal Dementia](/diseases/frontotemporal-disease)
- [ALS](/diseases/als)
- [TDP-43 Proteinopathy](/mechanisms/tdp-43-proteinopathy)
- [Lysosomal Dysfunction](/mechanisms/lysosomal-dysfunction)
- [Progranulin](/genes/grn)
- [C9orf72](/genes/c9orf72)
- [Microglia](/cell-types/microglia)
References
[Van Deerlin VM et al., Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions (2010)](https://pubmed.ncbi.nlm.nih.gov/20081855/)
[Rutherford NJ et al., TMEM106B, the risk gene for Frontotemporal Dementia, is regulated by the microRNA-132/212 cluster and affects progranulin pathways (2012)](https://pubmed.ncbi.nlm.nih.gov/22855798/)
[Finch N et al., TMEM106B risk variant is associated with TDP-43 pathology in aged brain (2011)](https://pubmed.ncbi.nlm.nih.gov/21968534/)
[Busch JI et al., Reduced TMEM106B in the dentate gyrus correlates with FTLD-TDP and aging (2013)](https://pubmed.ncbi.nlm.nih.gov/23838831/)
[Schwenk BM et al., TMEM106B regulates progranulin levels and the penetrance of FTLD in GRN mutation carriers (2014)](https://pubmed.ncbi.nlm.nih.gov/25008355/)
[Nichols N et al., TMEM106B effects on cortical structure in FTLD and AD (2015)](https://pubmed.ncbi.nlm.nih.gov/26453611/)
[Luo L et al., TMEM106B, a frontotemporal lobar dementia modifier, associates with FTD-3-linked CHMP2B (2015)](https://pubmed.ncbi.nlm.nih.gov/26467557/)
[Cheng N et al., Increased expression of the Frontotemporal Dementia risk factor TMEM106B causes C9orf72-dependent alterations in lysosomes (2016)](https://pubmed.ncbi.nlm.nih.gov/27559466/)
[Simons C et al., A Dementia-Associated Risk Variant near TMEM106B Alters Chromatin Architecture and Gene Expression (2017)](https://pubmed.ncbi.nlm.nih.gov/28942918/)
[Van Meensel J et al., TMEM106B: a master regulator of lysosomal function? (2019)](https://pubmed.ncbi.nlm.nih.gov/30632482/)
[Lynch C et al., TMEM106B Effect on cognition in Parkinson disease and Frontotemporal Dementia (2019)](https://pubmed.ncbi.nlm.nih.gov/31112389/)
[Gauthreaux MS et al., Genetic modifiers of TMEM106B-associated neuropsychiatric disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32681156/)
[Brett SE et al., The lysosomal protein TMEM106B interacts with GRN and regulates lysosomal function (2022)](https://pubmed.ncbi.nlm.nih.gov/35675859/)
[Chen-Plotkin AS et al., TMEM106B core deposition associates with TDP-43 pathology (2024)](https://pubmed.ncbi.nlm.nih.gov/38277418/)
[UniProt: TMEM106B - Q9NUM4](https://www.uniprot.org/uniprot/Q9NUM4)Pathway Diagram
The following diagram shows the key molecular relationships involving TMEM106B discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)
Pathway Diagram
The following diagram shows the key molecular relationships involving TMEM106B discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)